A multi-level gene-diet interaction analysis of fish oil supplementation and 14 circulating polyunsaturated fatty acids-related traits identifies the *FADS* and *GRP12* loci

Susan Adanna Ihejirika[1], Alexandra Huong Chiang[2], Aryaman Singh[2], Eunice Stephen[2], Han Chen[3], Kaixiong Ye[1,2]*

[1] Institute of Bioinformatics, University of Georgia, Athens, GA, 30602, USA

[2] Department of Genetics, University of Georgia, Athens, GA, 30602, USA

[3] Human Genetics Center, Department of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA

***Corresponding Author:**
Kaixiong Ye, PhD
Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East Green Street, Athens, GA 30602
Phone: 706-542-5898 Email: kaixiong.ye@uga.edu

Abstract

Fish oil supplements (FOS) are known to alter circulating levels of polyunsaturated fatty acids (PUFAs) among individuals but in a heterogeneous manner. These varied responses may result from unidentified gene-FOS interactions. To identify genetic factors that interact with FOS to alter the circulating levels of PUFAs, we performed a multi-level genome-wide interaction study (GWIS) of FOS on 14 plasma measurements in 200,060 unrelated European-ancestry individuals from the UK Biobank. From our single-variant tests, we identified genome-wide significant interacting SNPs ($P < 5 \times 10^{-8}$) in the *FADS1-FADS2* gene cluster for total omega-3, omega-3%, docosapentaenoic acid (DHA), DHA% and the omega-6 to omega-3 ratio. Among the interaction signals for omega-3%, the lead SNP, rs35473591 (C>CT, CT allele frequency = 0.34), had a lower association effect size in the FOS-taking group (β = 0.35 for allele C) than that in the group without FOS (β = 0.42). Likewise, the effect sizes of associations between FOS and omega-3% varied across the three genotype groups (β = 0.45, 0.50, and 0.59, respectively, in C/C, C/CT, and CT/CT). Our gene-level aggregate and transcriptome-wide interaction analyses identified significant signals at two loci, around *FADS1-FADS2* and *GRP12*. The contribution of genome-wide gene-FOS interactions to phenotypic variance was statistically significant in omega-3-related traits. This systemic gene-FOS GWIS contributes to our understanding of the genetic architecture of circulating PUFAs underlying FOS response and informs personalized dietary recommendations.

Introduction

Genetic[1-3] and environmental factors, such as diet[4-6], influence the circulating levels of polyunsaturated fatty acids (PUFAs). PUFAs are fatty acids with 18 to 24 carbons and multiple double bonds. They fall into two main families, omega-3 and omega-6, depending on which carbon the first double bond falls on from the methyl end of the carbon chain. PUFAs play crucial roles in various physiological processes, including immune function, cardiovascular health, brain development, and cognitive performance.[7-9] Alpha-linolenic acid (ALA) and linoleic acid (LA) are essential omega-3 and omega-6 fatty acids, respectively, that can only be obtained from dietary sources and act as precursors for synthesizing long-chain PUFAs.[7] Long-chain PUFAs can be obtained from diet or produced endogenously in the presence of the necessary precursors.[7] Fish oil supplements (FOS) are a rich, readily available source of long-chain omega-3 PUFAs, particularly eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA).[10] Additionally, FOS intake alters circulating PUFA concentrations similarly to fish consumption.[11]

The interactions between genetic variants and dietary PUFAs also influence circulating PUFA concentrations.[7,8,12-19] This means that omega-3 PUFAs obtained through FOS can alter the genetic effects on circulating PUFA levels, and that genetic variants can modify the effects of FOS on the same phenotypes. One of the relevant genetic loci, the *FADS* locus, contains the *FADS1* and *FADS2* genes, which encode the delta-5 (D5) and delta-6 (D6) desaturase enzymes, respectively. These membrane-bound enzymes introduce cis double bonds at the D5 and D6 positions in PUFAs, the rate-limiting steps

in long-chain PUFA biosynthesis.[20,21] Juan *et al.* found that higher dietary EPA and DHA consumption increases circulating EPA proportions.[12] However, genotypes at the rs174546 *FADS1* SNP (C>T) impacted the extent of that increase. For every 1-standard deviation (SD) increase in EPA intake, individuals with the C/C genotype saw an average increase of 3.7% in the circulating EPA level, while those with the T/T genotype saw an average increase of 7.8%. These gene-diet interactions may explain some of the heterogeneity in circulating PUFA levels in response to omega-3 PUFA supplementation.[22] Furthermore, these genotype-dependent responses may provide some insights into the inconsistent results in observational studies and randomized controlled trials (RCTs) investigating the effect of omega-3 PUFA supplementation on various outcomes,[8] such as the risk of cardiometabolic diseases, Alzheimer's disease, cancer, and inflammation.[23-27]

Despite advances in characterizing genetic loci interacting with dietary omega-3 PUFAs, most existing gene-dietary PUFAs interaction studies have various weaknesses and limitations. Most of them examined only candidate genes or variants[12-18]. Some were performed in specific contexts, such as disease risk and related outcomes[19,23-27], while others only examined circulating metabolites other than PUFAs as outcomes.[19,28] They were also limited by small sample sizes. This leaves a gap in understanding the effects of interactions between genome-wide loci and dietary omega-3 PUFAs on circulating PUFAs in a generally healthy cohort.

To this end, we conducted a large-scale gene-diet interaction analysis (N=200,060) of FOS on 14 circulating PUFAs-related measurements in the UK Biobank cohort[29,30] to systematically identify genetic factors that interact with FOS to alter levels of plasma PUFAs. We then performed a transcriptome-wide interaction study (TWIS) to identify genes whose expression interacts with FOS. Lastly, we estimated the phenotypic variance explained by genome-wide interactions with FOS. Our study is the first large-scale GWIS of FOS on the circulating levels of PUFAs.

Methods

Cohort

The UK Biobank is a large, population-based prospective study of over 500,000 volunteer participants recruited between 2006 and 2010 from across England, Wales, and Scotland. The participants were between the ages of 40 and 69 years. At recruitment, participants provided sociodemographic, lifestyle, environmental, clinical, and biochemical information through touchscreen questionnaires, face-to-face interviews, and physiological measurements. Plasma samples were provided for genotyping and nuclear magnetic resonance (NMR) spectroscopy-based metabolomic measurements.[29,30] The UK Biobank received ethical approval from the National Research Ethics Service Committee North West–Haydock (reference ID 11/ NW/0382). The use of participants' data in this study was approved under Project 48818.

Participant Inclusion and Exclusion

In this study, we restricted our participants to those who were of genetically determined European ancestry[31], did not have a high degree of kinship with other volunteers, were not outliers for heterozygosity or missing genotype rate, had matched self-reported and genetic sex, and had no sex chromosome aneuploidy (Figure S1). All UK Biobank participants provided written informed consent upon recruitment, authorizing the storage and use of their provided biological, medical, and genetic data for health-related research purposes. Additionally, participants who had withdrawn their consent as of February 22nd, 2022, were removed (N=114).

Genotype

The genotype data used in this study was version 3 of the UK Biobank genotyping release, previously described in detail.[29] This data included genotyping of ~820,000 variants done with either the UK BiLEVE Axiom Array or the UKB Axiom Array. It also included initial quality control and imputation of variants using a merged reference panel of the Haplotype Reference Consortium (HRC) and UK10K.[29] For further genotype QC, we selected only autosomal variants with imputation quality score (INFO) > 0.5, minor allele frequency (MAF) > 1%, genotype missingness per individual < 5%, genotype missingness per variant < 2%, and Hardy-Weinberg equilibrium (HWE) *p*-value < 1.0×10^{-6} using PLINK2 alpha-v2.3.[32]

Phenotype

Finland-based Nightingale Health Ltd. performed NMR metabolomic measurement of 251 metabolic biomarkers for approximately 280,000 participants. The UK Biobank released this data in two phases – Phases One and Two. Phase One release consisted of plasma measurements for 120,000 randomly selected samples. Phase Two consisted of measurements for individuals in Phase One and an additional 170,000 samples. Absolute circulating levels of fatty acids, including PUFAs and monounsaturated fatty acids (MUFAs), were measured and reported in mmol/L. The proportion of each PUFA to total fatty acids was expressed as a percentage. We investigated 14 circulating PUFAs and MUFAs-related traits as our outcomes. The 14 phenotypes were the absolute circulating levels of total PUFAs, total MUFAs, omega-3 PUFAs, omega-6 PUFAs, LA, and DHA; their relative percentages in total fatty acids

(i.e., PUFAs%, MUFAs%, omega-3%, omega-6%, LA%, and DHA%), and the ratios of PUFAs to MUFAs and omega-6 to omega-3. All phenotypes were rank-based inverse normal transformed.

Dietary Exposure

The primary exposure of interest in this study is FOS. We used the UK Biobank dietary questionnaire administered during recruitment to determine the exposure status. This questionnaire was a touchscreen survey about the intake frequency of common food and drink items. A total of 497,666 participants filled these out during the initial assessment center visit between 2006 and 2010. Participants were asked about mineral and other dietary supplements, “Do you regularly take any of the following? (You can select more than one answer)”, and “fish oil (including cod liver oil)” was one of the options (Data Field 6179).

Genome-wide Interaction Analysis

We performed single-variant interaction tests with the Gene-Environment interaction analysis in Millions of samples (GEM) tool.[33] GEM implements a generalized linear model for unrelated individuals. GEM conducts tests for marginal effects, interaction effects (1-degree of freedom tests), and joint tests for genetic main and interaction effects (2-degree of freedom tests). In this analysis, only results from the 1-degree of freedom (1df) test were interpreted due to our interest in strong interaction effects. We used age, sex, age-by-sex, and the first ten principal components as the covariates in

our model. Genome-wide significance *p*-value of 5.0×10^{-8} was used to define significant interactions.

To interpret the interaction signals identified by GEM, we used PLINK2 alpha-v2.3 to conduct exposure-stratified analysis to quantify SNP effects in each exposure group. Lastly, to quantify the effects of FOS across the genotype groups, we fitted linear models to each group and adjusted for the same covariates as in our single-variant interaction tests.

Gene-level Interaction Analysis

FUMA[34] was used to implement the MAGMA model[35], which maps variants to genes based on physical locations, aggregates *p*-values from the individual variant-FOS interaction tests across genic regions, and tests gene-level associations with each of the phenotypes of interest. Variants were mapped to 18,767 genes based on defined transcription start and stop sites, and a *p*-value of 2.66×10^{-6} (0.05/18767) was used to define statistical significance. Linkage disequilibrium (LD) was estimated using the UK Biobank release 2b 10k white British reference panel.

Transcriptome-wide Interaction Analysis

We used the MetaXcan framework for our TWIS to integrate eQTL information with single-variant GWIS summary statistics. MetaXcan tools include S-PrediXcan[36] and S-MultiXcan.[37] S-PrediXcan predicts and imputes genetically determined gene expression levels and tests their associations with the phenotype of interest. We used the MASHR-

based models to predict gene expression. These models are based on fine-mapped variants for each tissue. They take in gene expression weights, the variance and covariances of SNPs, and the beta coefficient of each SNP from summary statistics. S-MultiXcan aggregates information across all tissues. After multiple testing correction for the number of genes that had a prediction model in at least one tissue, significance was defined as $p < 2.9 \times 10^{-6}$ (0.05/17,500).

Estimation of Phenotypic Variance Explained by Gene-FOS Interactions

We performed GCTA-GREML[38] analysis to estimate the proportion of phenotypic variance explained by genome-wide gene-FOS interactions for each of the 14 phenotypes separately. We estimated the genetic relationship matrix (GRM) between pairs of individuals using LD-pruned SNPs. SNPs were pruned using a window size of 1000 variants, a step size of 100 variants, and an r^2 of 0.9.

To estimate the variance explained by the top variant, we assumed gene-environment independence and applied the formula

$$2\beta_{G\times E}^{2} f(1-f)p(1-p)$$

where β is the gene-FOS interaction effect size, *f* is the MAF, and *p* is the exposure prevalence in the population.

Results

Sample characteristics

NMR metabolite measurements for UK Biobank participants were released in two phases – Phase One (*N* = 120,000) and Phase Two (*N* = 170,000 additional samples). Phase Two release also included updated and corrected Phase One measurements (Methods). We refer to the additional 170,000 samples as Phase Two in this study. We performed exposure quality control on the combined dataset of 290,000 participants for our gene-FOS interaction analysis (Figure S1). Approximately 31.8% (*N* = 63,711) of 200,060 included participants indicated regular FOS use at recruitment (Table S1). The percentage of females and mean age in our dataset were 53.5% and 56.8 ± 8.0, respectively.

Variant-level analysis identified interacting SNPs in the *FADS* locus

We performed single-variant 1-df interaction tests to examine the interactions between FOS and genetic variants in the Phase One and Phase Two datasets, separately. We identified one and two unique loci at $p < 5.0 \times 10^{-8}$ in the Phase One and Two datasets, respectively (Tables S2 and S3, Figures S2, S3, and S4). The correlations between the *p*-values from both analyses are shown in Figure S3, with reproducible association signals observed for total omega-3, omega-3%, the omega-6/omega-3 ratio, DHA, and DHA%.

Next, we performed interaction tests in the combined dataset of Phase One and Two (Figure S5, Table S4). We identified genome-wide significant interaction effects for

variants in the *FADS1-FADS2* gene cluster, hereafter referred to as the *FADS* locus, for five traits, including total omega-3, omega-3%, DHA, DHA%, and the omega-6/omega-3 ratio (Figures 1A and S5, Table 1). To report our significant results, we focused on omega-3% as we observed similar trends in the other four traits. Omega-3% encompasses all omega-3 PUFAs and reflects omega-3 concentration in relation to total fatty acids. The most significant interaction was at the lead SNP rs35473591 (chr11:61586328; C>CT, MAF = 0.34) (Figure 1B). To quantify the genetic effect of rs35473591 in each exposure subgroup, we performed a stratified analysis (Figure 1C). The C allele had an overall positive effect on omega-3%, but its effect size was lower in the FOS-taking group (β_G = 0.35) than in the group that does not use FOS (β_G= 0.42). Furthermore, we fitted linear models to quantify the effect of FOS in each genotype subgroup. FOS significantly altered omega-3% levels. The degree of alteration varied across the three genotype groups (Figure 1D, β_E = 0.45, 0.50, 0.59 SD units, respectively, in C/C, C/CT, and CT/CT). Together, these results highlight a significant effect of interaction between rs35473591 and FOS on omega-3%, demonstrating that the effect of FOS on circulating omega-3% is modulated by rs35473591 genotype. Similar interaction effects were observed at the *FADS* locus for total omega-3, DHA, DHA%, and the omega-6/omega-3 ratio.

Gene-level interactions with FOS

To extend our single-variant tests, we first used MAGMA to aggregate interaction *p*-values across genic regions and performed gene-based interaction tests. The *FADS* cluster interaction was significant in the same five traits as in the single-variant tests

(Figure 2). Around this *FADS* locus, in addition to the *FADS1* and *FADS2* genes, the *FADS3, TMEM258, MYRF, FEN1,* and *RAB3IL1* genes were also significant across the same five traits (Figure 2A), but these signals may be driven by the same variants due to the high level of LD in this genomic region. Additionally, a novel locus around the *GPR12* gene was significant in total PUFAs% and the ratio of PUFAs to MUFAs (Figure 2B). The top SNP in PUFAs%, rs1752653 (chr 13:27322777; T>C, MAF = 0.21), reached suggestive genome-wide significance at $p < 5.0 \times 10^{-6}$ (Figure 3A). *GPR12*-rs1752653 had opposite directions of genetic effects on PUFAs% in the FOS and non-FOS-taking groups, with β_G = 0.03 and -0.01, respectively (Figure 3B). Across the three genotype groups, the effect of FOS on PUFAs% is β_E = 0.24, 0.21, and 0.16 SD units, respectively, in T/T, T/C, and C/C.

Next, we integrated eQTL information with our GWIS summary statistics using S-PrediXcan and S-MultiXcan. We first performed S-PrediXcan analyses to identify genes whose genetically predicted expression levels interact significantly with FOS intake status in each phenotype. S-PrediXcan conducted single-tissue analysis in 49 tissues available in the GTEx consortium. We used S-MultiXcan to aggregate results across multiple tissues and to increase power relative to the individual tissue analyses. After multiple testing correction for the number of genes that had a prediction model in at least one tissue (0.05/17,500; $p < 2.9 \times 10^{-6}$), we identified 24 significant interactions involving seven genes across five unique traits (Table S5). The *FADS1, FADS2, FADS3, TMEM258, FEN1, BEST1,* and *FTH1* genes were all significant across the same five traits as MAGMA gene-based analysis and our single-variant tests. The most

significant interaction was for the *FADS1* gene ($p = 8.8 \times 10^{-22}$) in omega-3%. The *FADS1* gene was also the only gene with interaction effects in all five phenotypes with significant interactions. In summary, two types of gene-based analyses consistently identified genes around the *FADS* locus to exhibit significant gene-FOS interaction signals for five PUFA traits. Gene-level analysis with MAGMA further identified the *GPR12* locus for total PUFAs% and the ratio of PUFAs to MUFAs.

Contribution of gene-FOS interactions to the phenotypic variance of circulating PUFA levels

We conducted GCTA-GREML analysis to estimate the amount of phenotypic variance explained by genome-wide gene-FOS interactions. The total additive genetic influence (i.e., SNP heritability) across all 14 PUFA and MUFA traits ranged from 14.2% to 23.9% (s.e. 0.36% and 0.37%) in LA and MUFAs%, respectively (Figure 4, Table S6). The phenotypic variance explained by genome-wide gene-FOS interactions ranged from 0.53% to 1.51% (s.e. 0.38% and 0.39%) in omega-6% to DHA%, respectively. These estimates were statistically significant in 10 out of 14 PUFA traits. The four traits without significant variance explained are total PUFAs, total MUFAs, MUFAs%, and omega-6%. We then estimated the contribution of the top SNP, rs35473591, to the variance explained by gene-FOS interactions in omega-3%. SNP rs35473591 explained a proportion of 5.12×10^{-4}, estimated to be 4.11% of the genome-wide gene-FOS interaction contributions to omega-3% variance. Gene-FOS interactions make small but non-negligible contributions to the phenotypic variance of plasma PUFA traits.

Discussion

In this study, we reported the most extensive GWIS of gene-FOS interactions in 14 PUFAs and MUFAs-related traits. Our goal for this project was to leverage a large cohort of over 200,000 European individuals in the UK Biobank to identify genetic loci that modify the associations between FOS and circulating PUFA traits. We also estimated the contribution of genome-wide interactions with FOS to the phenotypic variance. Across 14 traits, we identified significant gene-FOS interactions for seven traits – five variant and gene-level interactions in omega-3 related traits and the omega-6/omega-3 ratio, and two additional gene-level interactions for PUFAs% and PUFAs/MUFAs ratio.

In both our single-variant and gene-level analyses, we replicated the *FADS1-FADS2* gene cluster identified in previous gene-dietary PUFAs interaction studies.[12,39-41] These studies investigated other *FADS* SNPs in high LD with our top SNP, rs35473591. These variants do not all have the same effect on PUFAs, so it is essential to investigate each SNP's effect independently in the different PUFAs.[7] From our results, the lead *FADS1*-rs35473591 SNP had different effect sizes on omega-3% in the exposure groups. The genetic influence of this SNP was much more substantial in the individuals who do not take fish oil. This shows that FOS lessened the *FADS1*-rs35473591 effect on omega-3%, evidence of interaction. We also saw an overall increase in omega-3-related traits and a reduction in the omega-6 to omega-3 ratio after supplementation, indicating that FOS increases circulating omega-3 levels, as previously established.[4-6,42] The ratio of dietary omega-6 to omega-3 consumed has drastically shifted from ~5:1 to 10:1

because of our modern Western diets, and this is reflected in the ratio of plasma omega-6 to omega-3.[43] It is crucial to regulate this ratio because this shift has been associated with various chronic diseases.[8]

Our results showed that FOS intake had the lowest effect on omega-3% levels in the C/C homozygote genotype group and had the highest effect in the CT/CT group. The degree of omega-3% alteration increased with each copy of the CT allele. This implies that individuals with the CT/CT and C/CT genotypes will benefit more from taking FOS in terms of increasing omega-3 PUFA levels and reducing their omega-6/omega-3 ratio. Individuals who are homozygous of the C major allele at *FADS1*-rs35473591 benefit less, suggesting they need higher doses of FOS to attain the same circulating omega-3 levels as CT carriers. In summary, the *FADS1*-rs35473591 SNP, in the presence of FOS, has an increasing effect on omega-3-related traits, but the degree of this effect is genotype-dependent. We did not find any significant interaction for *FADS* variants in omega-6-related traits. Previous studies have implicated the *FADS* locus in interactions with PUFA supplementation.[13] A reasonable explanation is that our study focused on omega-3 PUFA supplementation (i.e., FOS), while Sergeant et al.[13] focused on supplementation of gamma-linolenic acid supplementation, which is an omega-6, 18-carbon PUFA.

Taking only genetic main or marginal effects into account does not give a complete picture of genetic impacts on circulating PUFAs. Accounting for relevant gene-environment interactions revealed patterns that would not be observed in a typical

genome-wide association study. Furthermore, revealing gene-environment interactions is needed to estimate how much phenotypic variance is explained by such interactions. This estimation gives a better understanding of complex traits and diseases because they are influenced by a combination of genetic makeup and environmental exposures, and the effects of some genes are environment-dependent. It also helps to explain some of the 'missing heritability' in traits. From our results, additive genetic factors alone explain a maximum of 22.5% of the phenotypic variance of omega-3-related plasma levels, while gene-FOS interactions explain a maximum of 1.51%. The contributions of gene-FOS interactions to omega-3 trait variance are small but non-negligible.

Our gene-based analysis revealed the G protein-coupled receptor 12 *(GPR12*) gene as an interacting locus for PUFAs% and the PUFAs to MUFAs ratio. This gene is highly expressed in the central nervous system and encodes the constitutively active G protein-coupled receptor 12 that promotes cyclic AMP production.[44] GPR12 is an orphan receptor, meaning it is unconfirmed what endogenous ligand it binds to.[44] Regarding PUFAs, it is unclear how the GPR12 receptor is associated with them. However, the GPR12 receptor is phylogenetically related to cannabinoid receptors, which bind to certain endocannabinoids, including omega-6-derived endocannabinoids.[45,46] Recent evidence shows that omega-3-derived endocannabinoids also exist.[45,46] Future research to experimentally establish a connection between PUFAs-derived endocannabinoids and the GPR12 receptor will support our findings.

A significant strength of our study is the large sample with complete dietary, genomic, and NMR PUFA information. We also performed our analyses at both the variant and gene levels and estimated the contributions of genome-wide gene-FOS interactions to the phenotypic variance of circulating PUFA traits, providing the most extensive analysis of gene-FOS interactions. However, our study has several limitations. Firstly, we restricted this study to European-ancestry participants and did not have large enough datasets to replicate these results in other populations. Large enough datasets with the necessary exposure, genomic, and phenotypic information to detect interactions are still uncommon. Secondly, for FOS information, we relied on only one dietary questionnaire administered to participants at one time point. This questionnaire did not give estimates of the frequency of FOS intake, such as daily or weekly. It also did not provide information on the types and compositions of FOS. Hence, we could not account for dosage heterogeneity in our model. Thirdly, other dietary sources of omega-6 and omega-3 PUFAs, such as vegetable oils and fatty fish, can alter circulating PUFA levels.[5,6,42] Furthermore, FOS status is correlated with other lifestyle and socioeconomic factors.[47] There is a possibility that the significant interactions we observed in our results were instead driven by other exposures that we did not explore in this study. However, our study had enough statistical power and was rigorous enough to replicate the *FADS* locus, giving credibility to our findings.

Conclusion

Our study revealed a novel locus that significantly alters the effect of FOS on PUFAs-related traits. Taking genetic information into account when making nutritional

recommendations is the hallmark of precision nutrition, which aims to move away from a one-size-fits-all dietary recommendation model. Variants that influence the effects of dietary PUFAs on plasma PUFAs will help inform diet-based disease prevention and treatment strategies. Additionally, accounting for gene-FOS interactions will aid in developing more accurate polygenic scores for PUFAs-related traits or PUFAs-associated diseases. Lastly, our study also brings to light a potentially unexplored association between the GPR12 gene and PUFAs. A future research direction to experimentally validate this association may highlight PUFA supplementation as a potential treatment for GPR12-related diseases, such as schizophrenia.[48]

Description of Supplemental Information

Supplemental information includes five figures and six tables.

Declaration of Competing Interests

The authors declare no conflict of interest.

Acknowledgments

We would like to acknowledge and express gratitude to the UK Biobank participants and administrative staff. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institutes of Health.

Data and Code Availability

Data processed in this study was made available through the UK Biobank and accessed via an approved application. Data are not publicly available and can be accessed by applying through https://www.ukbiobank.ac.uk/enable-your-research/register. Summary statistics will be available in the GWAS Catalog (https://www.ebi.ac.uk/gwas/) after publication. Scripts used to process the data, perform analysis, and interpret results are available on GitHub (https://github.com/adannasusan/PUFA-GxE).

References

1. Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K., Nettleton, J.A., King, I.B., Weng, L.C., Bhattacharya, S., et al. (2011). Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet *7*, e1002193. 10.1371/journal.pgen.1002193.
2. Guan, W., Steffen, B.T., Lemaitre, R.N., Wu, J.H.Y., Tanaka, T., Manichaikul, A., Foy, M., Rich, S.S., Wang, L., Nettleton, J.A., et al. (2014). Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet *7*, 321-331. 10.1161/CIRCGENETICS.113.000208.
3. Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A., Clark, J., Olthoff, B., Larson, M., Harris, W., and Shearer, G.C. (2015). A genome-wide association study of saturated, mono- and polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study. Prostaglandins Leukot Essent Fatty Acids *94*, 65-72. 10.1016/j.plefa.2014.11.007.
4. Schuchardt, J.P., Ostermann, A.I., Stork, L., Kutzner, L., Kohrs, H., Greupner, T., Hahn, A., and Schebb, N.H. (2016). Effects of docosahexaenoic acid supplementation on PUFA levels in red blood cells and plasma. Prostaglandins Leukot Essent Fatty Acids *115*, 12-23. 10.1016/j.plefa.2016.10.005.
5. Hodge, A.M., Simpson, J.A., Gibson, R.A., Sinclair, A.J., Makrides, M., O'Dea, K., English, D.R., and Giles, G.G. (2007). Plasma phospholipid fatty acid composition as a biomarker of habitual dietary fat intake in an ethnically diverse cohort. Nutr Metab Cardiovasc Dis *17*, 415-426. 10.1016/j.numecd.2006.04.005.
6. Huybrechts, I., Jacobs, I., Aglago, E.K., Yammine, S., Matta, M., Schmidt, J.A., Casagrande, C., Nicolas, G., Biessy, C., Van Puyvelde, H., et al. (2023). Associations between Fatty Acid Intakes and Plasma Phospholipid Fatty Acid Concentrations in the European Prospective Investigation into Cancer and Nutrition. Nutrients *15*. 10.3390/nu15173695.
7. Chilton, F.H., Murphy, R.C., Wilson, B.A., Sergeant, S., Ainsworth, H., Seeds, M.C., and Mathias, R.A. (2014). Diet-gene interactions and PUFA metabolism: a potential contributor to health disparities and human diseases. Nutrients *6*, 1993-2022. 10.3390/nu6051993.
8. Chilton, F.H., Dutta, R., Reynolds, L.M., Sergeant, S., Mathias, R.A., and Seeds, M.C. (2017). Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases. Nutrients *9*. 10.3390/nu9111165.
9. Tapiero, H., Ba, G.N., Couvreur, P., and Tew, K.D. (2002). Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother *56*, 215-222. 10.1016/s0753-3322(02)00193-2.
10. Saravanan, P., Davidson, N.C., Schmidt, E.B., and Calder, P.C. (2010). Cardiovascular effects of marine omega-3 fatty acids. Lancet *376*, 540-550. 10.1016/S0140-6736(10)60445-X.
11. Harris, W.S., Pottala, J.V., Sands, S.A., and Jones, P.G. (2007). Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells

and plasma phospholipids. Am J Clin Nutr *86*, 1621-1625. 10.1093/ajcn/86.5.1621.

12. Juan, J., Huang, H., Jiang, X., Ardisson Korat, A.V., Song, M., Sun, Q., Willett, W.C., Jensen, M.K., and Kraft, P. (2018). Joint effects of fatty acid desaturase 1 polymorphisms and dietary polyunsaturated fatty acid intake on circulating fatty acid proportions. Am J Clin Nutr *107*, 826-833. 10.1093/ajcn/nqy025.
13. Sergeant, S., Hallmark, B., Mathias, R.A., Mustin, T.L., Ivester, P., Bohannon, M.L., Ruczinski, I., Johnstone, L., Seeds, M.C., and Chilton, F.H. (2020). Prospective clinical trial examining the impact of genetic variation in FADS1 on the metabolism of linoleic acid- and □-linolenic acid-containing botanical oils. Am J Clin Nutr *111*, 1068-1078. 10.1093/ajcn/nqaa023.
14. Saleh, R.N.M., West, A.L., Ostermann, A.I., Schebb, N.H., Calder, P.C., and Minihane, A.M. (2021). APOE Genotype Modifies the Plasma Oxylipin Response to Omega-3 Polyunsaturated Fatty Acid Supplementation in Healthy Individuals. Front Nutr *8*, 723813. 10.3389/fnut.2021.723813.
15. Tomaszewski, N., He, X., Solomon, V., Lee, M., Mack, W.J., Quinn, J.F., Braskie, M.N., and Yassine, H.N. (2020). Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial. J Alzheimers Dis *74*, 975-990. 10.3233/JAD-191017.
16. Yassine, H.N., Rawat, V., Mack, W.J., Quinn, J.F., Yurko-Mauro, K., Bailey-Hall, E., Aisen, P.S., Chui, H.C., and Schneider, L.S. (2016). The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther *8*, 25. 10.1186/s13195-016-0194-x.
17. Stephensen, C.B., Armstrong, P., Newman, J.W., Pedersen, T.L., Legault, J., Schuster, G.U., Kelley, D., Vikman, S., Hartiala, J., Nassir, R., et al. (2011). ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation. J Lipid Res *52*, 991-1003. 10.1194/jlr.P012864.
18. Armstrong, P., Kelley, D.S., Newman, J.W., Staggers, F.E., Sr., Hartiala, J., Allayee, H., and Stephensen, C.B. (2012). Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. J Nutr *142*, 1417-1428. 10.3945/jn.112.159814.
19. Veenstra, J., Kalsbeek, A., Westra, J., Disselkoen, C., Smith, C., and Tintle, N. (2017). Genome-Wide Interaction Study of Omega-3 PUFAs and Other Fatty Acids on Inflammatory Biomarkers of Cardiovascular Health in the Framingham Heart Study. Nutrients *9*. 10.3390/nu9080900.
20. Ralston, J.C., Matravadia, S., Gaudio, N., Holloway, G.P., and Mutch, D.M. (2015). Polyunsaturated fatty acid regulation of adipocyte FADS1 and FADS2 expression and function. Obesity (Silver Spring) *23*, 725-728. 10.1002/oby.21035.
21. Merino, D.M., Ma, D.W., and Mutch, D.M. (2010). Genetic variation in lipid desaturases and its impact on the development of human disease. Lipids Health Dis *9*, 63. 10.1186/1476-511X-9-63.
22. Madden, J., Williams, C.M., Calder, P.C., Lietz, G., Miles, E.A., Cordell, H., Mathers, J.C., and Minihane, A.M. (2011). The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased

fish oil fatty acids intakes. Annu Rev Nutr *31*, 203-234. 10.1146/annurev-nutr-010411-095239.

23. Schulze, M.B., Minihane, A.M., Saleh, R.N.M., and Riserus, U. (2020). Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases. Lancet Diabetes Endocrinol *8*, 915-930. 10.1016/S2213-8587(20)30148-0.

24. Huang, L., Zhang, F., Xu, P., Zhou, Y., Liu, Y., Zhang, H., Tan, X., Ge, X., Xu, Y., Guo, M., and Long, Y. (2023). Effect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials. Adv Nutr *14*, 629-636. 10.1016/j.advnut.2023.04.009.

25. Wu, S., Ding, Y., Wu, F., Li, R., Hou, J., and Mao, P. (2015). Omega-3 fatty acids intake and risks of dementia and Alzheimer's disease: a meta-analysis. Neurosci Biobehav Rev *48*, 1-9. 10.1016/j.neubiorev.2014.11.008.

26. Kavyani, Z., Musazadeh, V., Fathi, S., Hossein Faghfouri, A., Dehghan, P., and Sarmadi, B. (2022). Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis. Int Immunopharmacol *111*, 109104. 10.1016/j.intimp.2022.109104.

27. Wei, L., Wu, Z., and Chen, Y.Q. (2022). Multi-targeted therapy of cancer by omega-3 fatty acids-an update. Cancer Lett *526*, 193-204. 10.1016/j.canlet.2021.11.023.

28. Francis, M., Li, C., Sun, Y., Zhou, J., Li, X., Brenna, J.T., and Ye, K. (2021). Genome-wide association study of fish oil supplementation on lipid traits in 81,246 individuals reveals new gene-diet interaction loci. PLoS Genet *17*, e1009431. 10.1371/journal.pgen.1009431.

29. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature *562*, 203-209. 10.1038/s41586-018-0579-z.

30. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med *12*, e1001779. 10.1371/journal.pmed.1001779.

31. Karczewski, K.J., Gupta, R., Kanai, M., Lu, W., Tsuo, K., Wang, Y., Walters, R.K., Turley, P., Callier, S., Shah, N.N., et al. (2024). Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and resolution into ancestry-enriched effects. medRxiv, 2024.2003.2013.24303864. 10.1101/2024.03.13.24303864.

32. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience *4*, 7. 10.1186/s13742-015-0047-8.

33. Westerman, K.E., Pham, D.T., Hong, L., Chen, Y., Sevilla-Gonzalez, M., Sung, Y.J., Sun, Y.V., Morrison, A.C., Chen, H., and Manning, A.K. (2021). GEM: scalable and flexible gene-environment interaction analysis in millions of samples. Bioinformatics *37*, 3514-3520. 10.1093/bioinformatics/btab223.

34. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping and annotation of genetic associations with FUMA. Nat Commun *8*, 1826. 10.1038/s41467-017-01261-5.
35. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol *11*, e1004219. 10.1371/journal.pcbi.1004219.
36. Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M., Torstenson, E.S., Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat Commun *9*, 1825. 10.1038/s41467-018-03621-1.
37. Barbeira, A.N., Pividori, M., Zheng, J., Wheeler, H.E., Nicolae, D.L., and Im, H.K. (2019). Integrating predicted transcriptome from multiple tissues improves association detection. PLoS Genet *15*, e1007889. 10.1371/journal.pgen.1007889.
38. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, D.R., Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., et al. (2010). Common SNPs explain a large proportion of the heritability for human height. Nat Genet *42*, 565-569. 10.1038/ng.608.
39. Takkunen, M.J., de Mello, V.D., Schwab, U.S., Kuusisto, J., Vaittinen, M., Agren, J.J., Laakso, M., Pihlajamaki, J., and Uusitupa, M.I. (2016). Gene-diet interaction of a common FADS1 variant with marine polyunsaturated fatty acids for fatty acid composition in plasma and erythrocytes among men. Mol Nutr Food Res *60*, 381-389. 10.1002/mnfr.201500594.
40. Roke, K., and Mutch, D.M. (2014). The role of FADS1/2 polymorphisms on cardiometabolic markers and fatty acid profiles in young adults consuming fish oil supplements. Nutrients *6*, 2290-2304. 10.3390/nu6062290.
41. Al-Hilal, M., Alsaleh, A., Maniou, Z., Lewis, F.J., Hall, W.L., Sanders, T.A., O'Dell, S.D., and team, M.s. (2013). Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. J Lipid Res *54*, 542-551. 10.1194/jlr.P032276.
42. Ma, J., Folsom, A.R., Shahar, E., and Eckfeldt, J.H. (1995). Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin Nutr *62*, 564-571. 10.1093/ajcn/62.3.564.
43. Blasbalg, T.L., Hibbeln, J.R., Ramsden, C.E., Majchrzak, S.F., and Rawlings, R.R. (2011). Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr *93*, 950-962. 10.3945/ajcn.110.006643.
44. Brown, K.J., Laun, A.S., and Song, Z.H. (2017). Cannabidiol, a novel inverse agonist for GPR12. Biochem Biophys Res Commun *493*, 451-454. 10.1016/j.bbrc.2017.09.001.
45. Laun, A.S., Shrader, S.H., Brown, K.J., and Song, Z.H. (2019). GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin *40*, 300-308. 10.1038/s41401-018-0031-9.

46. Cascio, M.G. (2013). PUFA-derived endocannabinoids: an overview. Proc Nutr Soc *72*, 451-459. 10.1017/S0029665113003418.
47. Cundiff, D.K., Lanou, A.J., and Nigg, C.R. (2007). Relation of omega-3 Fatty Acid intake to other dietary factors known to reduce coronary heart disease risk. Am J Cardiol *99*, 1230-1233. 10.1016/j.amjcard.2006.12.032.
48. Lu, Y., Hatzipantelis, C.J., Langmead, C.J., and Stewart, G.D. (2023). Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia. Br J Pharmacol. 10.1111/bph.16221.

Figure titles and legends

Figure 1. *FADS* variants with significant interaction signals ($p < 5.0 \times 10^{-8}$) in five PUFA traits. A) Circular Manhattan plots of *p*-values for gene-FOS interactions on omega-3, omega-3%, DHA, DHA%, and the ratio of omega-6 to omega-3. B) LocusZoom plot of the *FADS* locus for omega-3%. C) Marginal genetic effect of rs35473591 on omega-3% in stratified exposure subgroups. D) Marginal exposure effects of FOS on omega-3% in stratified genotype subgroups. All error bars represent 95% confidence intervals.

Figure 2. Significant gene-level interactions for Omega-3% and PUFAs%. Gene-level Manhattan plots from MAGMA analysis for genes that reached the significance threshold of $p < 2.66 \times 10^{-6}$ in A) Omega-3% and B) PUFAs%, C) Marginal genetic effect of rs1752653 on PUFAs% in stratified exposure subgroups. Error bars show 95% confidence intervals. D) Marginal exposure effects of FOS on PUFAs% in stratified genotype subgroups. Error bars represent 95% confidence intervals.

Figure 3. *GPR12* variant with suggestive genome-wide significance ($p < 5.0 \times 10^{-6}$) in PUFAs%. A) LocusZoom plot of the *GPR12* locus for PUFAs%. B) Marginal genetic effect of rs1752653 on PUFAs% in stratified exposure subgroups. C) Marginal exposure effects of FOS on PUFAs% in stratified genotype subgroups. All error bars represent 95% confidence intervals.

Figure 4. The proportion of phenotypic variance explained by genome-wide gene-FOS interactions in the combined dataset.

Supplementary Figures

Figure S1. Participant flowchart.

Figure S2. Manhattan and QQ plots of p-values for gene-FOS interactions in 14 PUFAs and MUFAs-related phenotypes for 85,708 participants in the Phase One dataset.

Figure S3. Scatter plots of *p*-values, across the genome, of gene-FOS interactions across 14 PUFAs and MUFAs-related phenotypes in the Phases One and Two datasets.

Figure S4. Manhattan and QQ plots of p-values for gene-fish oil interactions in 14 PUFAs and MUFAs-related phenotypes for 114,352 participants in the Phase Two dataset.

Figure S5. Manhattan and QQ plots of p-values for gene-fish oil interactions in 14 PUFAs and MUFAs-related phenotypes for 200,060 participants in the combined dataset.

Supplementary Tables

Table S1. Baseline characteristics of participants in Phase One, Phase Two, and combined releases of NMR metabolite data of individuals of European ancestry in UK Biobank

Table S2. GWIS summary statistics of significant and suggestive gene-FOS interactions in 14 PUFAs and MUFAs-related phenotypes for 85,708 participants in the Phase One dataset

Table S3. GWIS summary statistics of significant and suggestive gene-FOS interactions in 14 PUFAs and MUFAs-related phenotypes for 114,352 participants in the Phase Two dataset

Table S4. GWIS summary statistics of significant and suggestive gene-FOS interactions in 14 PUFAs and MUFAs-related phenotypes for 200,060 participants in the combined dataset

Table S5. S-MultiXcan summary of gene-tissue associations

Table S6. Estimates of SNP-based heritability and phenotypic variance explained by gene-FOS interactions

Table 1. Lead SNPs in traits with genome-wide significant interaction signals. All significant variants are in the *FADS1-FADS2* gene cluster.

rsID	Chr	Pos	Nearest gene	EA (frequency)	NEA	PUFA trait	Interaction *p*-value	Interaction Beta	Interaction S.E.
rs35473591	11	61586328	*FADS1-FADS2*	C (0.66)	CT	Omega-3%	2.50×10^{-23}	-0.0722	0.00726
						Omega-6 to Omega-3 ratio	1.09×10^{-20}	0.0672	0.00720
						Omega-3	2.74×10^{-17}	-0.0595	0.00704
						DHA	1.56×10^{-12}	-0.0492	0.00696
rs174535	11	61551356	*MYRF*	T (0.65)	C	DHA%	4.11×10^{-8}	-0.0390	0.00718

EA, effect allele; NEA, non-effect allele; S.E., standard error


A
Chr1
Chr2
Chr3
Chr4
Chr5
Chr6
Chr7
Chr8
Chr9
Chr10
Chr11
Chr12
Chr13
Chr14
Chr15
Chr16
Chr17
Chr18
Chr19
Chr20
Chr21
Chr22
23
17.25
11.5
5.75
0
rs35473591
rs35473591
rs35473591
rs35473591
rs174535
Omega-6/Omega-3 Ratio
Omega-3
Omega-3%
DHA
DHA%
Significant SNPs
B
LD (r²)
1
0.8
0.6
0.4
0.2
0
rs35473591
-log10 p-value
Recombination Rate (cM/Mb)
Chromosome 11 (Mb)
61.40
61.50
61.60
61.70
DAGLA→
MYRF→
FADS2→
←RAB3IL1
←FTH1
←TMEM258
←FADS3
BEST1→
FEN1→
←FADS1
C
β of rs35473591 on omega-3%
0.425
0.400
0.375
0.350
Does not take fish oil
Takes fish oil
C/C
C/CT
CT/CT
D
β of FOS on omega-3%
0.60
0.55
0.50
0.45


A
-log10 P-value
MYRF
TMEM258
FADS2
FEN1
FADS1
FADS3
RAB3IL1
B
-log10 P-value
GPR12


A
LD (r²)
1
0.8
0.6
0.4
0.2
0
rs1752653
-log10 p-value
Recombination Rate (cM/Mb)
Chromosome 13 (Mb)
27.20
27.30
27.40
27.50
WASF3→
←GPR12
B
β of rs1752653 on PUFAs%
Does not take fish oil
Takes fish oil
C
β of FOS on PUFAs%
C/C
C/T
T/T


Variance explained by gene-FOS interactions
0.25
0.20
0.15
0.10
0.05
0.00
LA
LA%
DHA
DHA%
MUFAs
MUFAs%
PUFAs
PUFAs%
Omega-3
Omega-3%
Omega-6
Omega-6%
PUFAs/MUFAs
Omega-6/Omega-3
Circulating PUFAs and MUFAs phenotype